Drugs / Zinc gluconate
Zinc gluconate
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05085834 | Jan 2020 → Aug 2024 | cardiovascular disorder, disorder of zinc metabolism | University Hospitals Cleveland Medical Center | Completed | Mixed |
| Phase 0 | NCT03957720 | Mar 2019 → Dec 2024 | Wilson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01984580 | Apr 2011 → Mar 2015 | Barrett esophagus | Main Line Health | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05892770 | Aug 2023 → Dec 2025 overdue | spasmodic dystonia | University of Florida | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05003492 | Sep → Oct 2021 | COVID-19 | Amr kamel khalil Ahmed | Unknown | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 2 | NCT00228332 | Apr 2004 → Mar 2006 | common wart | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05527899 | May 2022 → Jun 2024 | disorder of zinc metabolism | Tufts University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00495690 | Nov 2004 → Nov 2007 | diarrheal disease, infectious disease with sepsis, meningitis, pneumonia | Society for Applied Studies | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT05835037 | Feb 2024 → Jul 2028 expected | hyperglycemia, prediabetes syndrome | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 4 | NCT01403532 | Sep 2009 → Dec 2012 | Kallmann syndrome | Shanghai Jiao Tong University School of Medicine | Completed | Met primary |
| Phase not applicable3 trials | ||||||
| — | NCT07270042 | Dec 2025 → Sep 2026 overdue | masticatory muscles, hypertrophy of | Latakia University | Not yet recruiting | No outcome recorded |
| — | NCT06856590 | Feb → Sep 2025 | hand-foot syndrome | Gazi University | Completed | No outcome recorded |
| — | NCT02951715 | Dec 2013 → Dec 2014 | disorder of zinc metabolism, noise induced hearing loss, tinnitus | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1/2 | NCT00692224 Comparator | Oct 2005 → Oct 2006 | — | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT06290219 Background | Mar → Sep 2024 | anosmia | Taichung Veterans General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00809809 Comparator | Dec 2008 → Sep 2009 | herpes labialis | Integrative Medicine Institute | Completed | No outcome recorded |
| Phase 4 | NCT01468636 Comparator | Nov 2011 → Jan 2012 | anogenital human papillomavirus infection | University of British Columbia | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zinc gluconate | “Participants assigned to zinc-containing arms will receive oral zinc gluconate supplementation (78 mg twice daily) for 8 weeks.” NCT06856590 ↗16“Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days” NCT05003492 ↗ “Zinc gluconate 50 mg orally once daily for 4 days prior to injections.” NCT07270042 ↗ “Oral swabs containing homeopathic Zinc gluconate” NCT00809809 ↗ “200 mg BID of oral zinc gluconate x 8 weeks” NCT01468636 ↗ “Zinc gluconate 20mg,P.O, twice daily” NCT01403532 ↗ |
| Known as | Bis(d-gluconato-o1,o2) zinc | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833377 ↗ |
| Known as | Gluconic acid zinc complex | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833377 ↗ |
| Known as | Zinc d-gluconate (1:2) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833377 ↗ |
| Known as | Zincum gluconicum | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833377 ↗ |
| Known as | zinkgluconaat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00228332 ↗ |
| Action | Inhibit | “Zinc salts irreversibly inhibit herpes virus replication in vitro” NCT00809809 ↗ |
| Modality | Small molecule | — CHEMBL3833377 ↗ |
| Route | Oral | “Oral zinc gluconate (5 mg elemental)” NCT00495690 ↗ |